Topic Archives: Abbvie (ABBV)

Jimmy Mengel’s “Delta-9” — is it “One Drug to End All Pain — Naturally?”

“The Greatest Medical Breakthrough in 72 Years… “One Drug to End All Pain — Naturally “A new revolutionary drug called ‘Delta-9’ will send a small group of companies skyrocketing for life-altering gains… starting December 31, 2014. “The last time something like this happened 72 years ago… investors had the opportunity to turn every $1,000 into […]

Another Hot Australian Biotech: Is Biotron Right for Your Portfolio?

[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice.  As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]

Comments

  • SoGiAm

    AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment Today 8:12 AM ET (MarketWatch) Sh...

  • SoGiAm

    $ENTA $ABBV MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available in Japan for the Treatment of Chronic Hepatitis C Acr...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.